Diana Chung

Diana Chung is an experienced clinical development leader with a robust background in managing international clinical trials across various therapeutic areas. Currently serving as Chief Development Officer at SiteOne Therapeutics, Inc., since May 2024, Diana previously held multiple senior roles at Terns Pharmaceuticals, including Senior Vice President and Chief Development Officer. Prior to that, Diana provided consultancy services in clinical operations and medical affairs. At Gilead Sciences, Diana advanced from Director to Executive Director, overseeing clinical development operations and ensuring the successful management of Phase I to IV trials. Diana holds a Master’s degree in Molecular & Cell Biology from the University of Maryland, Baltimore, and a Bachelor of Applied Science in Biochemistry from Case Western Reserve University.